Equity-Method Investment and Other Investments - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jul. 30, 2021
Schedule of Equity Method Investments [Line Items]
Loss from equity method investment		$ (3,048)	$ (2,745)
Equity method investment		28,389		$ 32,455
Preferred Stock Purchase Agreement [Member] | Joint Venture Aven Cell [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage					33.33%
Preferred Stock Purchase Agreement [Member] | Cellex and BXLS [Member] | Joint Venture Aven Cell [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage					66.67%
AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value					$ 62,900
Investments in and Advances to Affiliates, at Fair Value, Gross Reductions		1,300
Loss from equity method investment		2,800
Equity method investment		28,400
Sparing Vision [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value	$ 14,800
Sparing Vision [Member] | Series A2 Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	83,316
Kyverna Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, at Fair Value		$ 10,000
Kyverna Therapeutics Inc [Member] | Series B Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		3,739,515
Fair value of stock received		$ 7,000
Number of stock additionally invested		1,602,649
Cash consideration received on sale of common stock		$ 3,000